What sector does ResMed belong to?

ResMed operates in the Health Care sector, specifically the Health Care Equipment industry, and is listed on the US markets.

What is the current share price of RMD?

As of the latest available quote, RMD traded at $218.27. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of RMD?

ResMed has a price-to-earnings (P/E) ratio of about 20.93. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of RMD?

The market capitalisation of ResMed is approximately $31.88B.

Is ResMed profitable?

For its latest reported financial year, ResMed recorded a net profit margin of about 26.94%.

Does RMD pay a dividend?

ResMed currently has a dividend yield of about 1.09%.

What is the return on equity (ROE) of RMD?

ResMed has a return on equity (ROE) of about 23.13%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of RMD?

Over the past 52 weeks, RMD has traded between a low of $180.27 and a high of $284.87.

ResMed

RMD US Health Care Health Care Equipment

S&P 500

$218.27

-0.60%

Delayed · cached 15 min

Fair value analysis

RMD

ResMed

$218.27

Close used for this calculation

$195.98Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

66/100

Profitability21/25

Returns13/25

Balance Sheet23/25

Efficiency9/25

Growth9/25

Strong

Quality radar

Consensus fair value

$195.98

Near FV

▼ -10.2% against the close used

Model range $102.87 – $242.98

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$102.87Fair value$195.98Bull$242.98

FairClose

52-week traded range

52W low $182.8252W high $283.28

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

ResMed closed at $218.27, 11.4% above the consensus fair value of $195.98 drawn from 9 valuation models.

Financial DNA score 66/100 — Strong. P/E of 20.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$224.18

+2.7%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$102.87

-52.9%

√(22.5 × EPS × BVPS)

EPS=10.43, BVPS=45.1 · outside Graham range (P/E 20.9, P/B 4.8) — asset-light, treat as a rough floor

P/E Fair Value

$208.60

-4.4%

EPS × 20x (sector P/E)

EPS=10.43, Sector P/E=20x

Peter Lynch (PEG)

$145.92

-33.1%

EPS × Growth% (PEG = 1 is fair)

EPS=10.43, g=14%

EV/EBITDA

$242.98

+11.3%

(EBITDA × 17x − Net Debt) ÷ Shares

EBITDA=2.09B

Dividend Discount (DDM)

$129.65

-40.6%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=2.4, r=10%, g=8%

Book Value (P/B)

$193.13

-11.5%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=45.1, ROE=23.1%, g=6%, r=10%

Reverse DCF

$218.27

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 7.8% | Historical: 14%

Margin of Safety

$133.91

-38.6%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=178.55, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer